WilmerHale Advises Inozyme Pharma in $67 Million Series A2 Financing

WilmerHale Advises Inozyme Pharma in $67 Million Series A2 Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On April 10, 2019, Inozyme Pharma, Inc., a biotechnology company developing novel medicines to treat rare, debilitating, and life-threatening mineralization disorders, announced that it raised $67 million in a Series A2 financing led by Pivotal bioVenture Partners and Sofinnova Investments. Cross-over investors, including RA Capital Management, Cowen Healthcare Investments, and Rock Springs Capital, as well as Inozyme’s previous investors, Longitude Capital, NEA, Novo Holdings, and Sanofi Ventures, also joined this round.

Brian Johnson led the WilmerHale team representing Inozyme in this transaction which included Peter Roth and Andrea Sorrentino.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel